Literature DB >> 1650193

Illegitimate (or ectopic) transcription proceeds through the usual promoters.

J Chelly1, J P Hugnot, J P Concordet, J C Kaplan, A Kahn.   

Abstract

Illegitimate transcription corresponds to the low level presence of specific transcripts in nonspecific cells. This phenomenon allows to analyse any tissue-specific disease transcript in any easily accessible cell. We demonstrate here that the start sites of transcription are the same in specific and non-specific cells, which indicates that illegitimate transcription is due to a low level activity of the normal promoter. In addition, it is possible to increase about 10 fold the abundance of illegitimate transcripts through the use of cycloheximide. This treatment should, therefore, facilitate detection and qualitative analysis of illegitimate transcripts.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1650193     DOI: 10.1016/0006-291x(91)90143-u

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  The KLHL1-antisense transcript ( KLHL1AS) is evolutionarily conserved.

Authors:  Kellie A Benzow; Michael D Koob
Journal:  Mamm Genome       Date:  2002-03       Impact factor: 2.957

2.  Taking advantage of an old concept, "illegitimate transcription", for a proposed novel method of genetic diagnosis of McArdle disease.

Authors:  Ines Garcia-Consuegra; Alberto Blázquez; Juan Carlos Rubio; Joaquín Arenas; Alfonsina Ballester-Lopez; Adrián González-Quintana; Antoni L Andreu; Tomàs Pinós; Jaume Coll-Cantí; Alejandro Lucia; Gisela Nogales-Gadea; Miguel A Martín
Journal:  Genet Med       Date:  2016-02-25       Impact factor: 8.822

3.  Detection of cytokeratins 19/20 and guanylyl cyclase C in peripheral blood of colorectal cancer patients.

Authors:  S A Bustin; V G Gyselman; N S Williams; S Dorudi
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

4.  Oncofoetal fibronectin--a tumour-specific marker in detecting minimal residual disease in differentiated thyroid carcinoma.

Authors:  E Hesse; P B Musholt; E Potter; T Petrich; M Wehmeier; R von Wasielewski; R Lichtinghagen; T J Musholt
Journal:  Br J Cancer       Date:  2005-09-05       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.